R&D | December 31, 2025
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Applications include detailed scientific rationale and supporting clinical evidence
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The expansion includes a larger technical and service team and increased local procurement
Subscribe To Our Newsletter & Stay Updated
